SCHEMBL17674718

SCHEMBL17674718

Cc1cccc(Cl)c1NC(=O)N1CCc2ccccc2[C@@H]1C

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 3/20 0.60
▸ NPC1 O15118 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ XIAP P98170 2/20 0.45
▸ TAS1R3 Q7RTX0 1/20 0.45
▸ TAS1R1 Q7RTX1 1/20 0.45
▸ TAS1R2 Q8TE23 1/20 0.45
▸ GAA P10253 1/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LIPE Q05469 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ DRD4 P21917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17674575 0.93 DRD1 (0.67) DRD1NPC1POLBXIAPTAS1R3
SCHEMBL17674681 0.93 DRD1 (0.67) DRD1NPC1POLBXIAPTAS1R3
SCHEMBL17674616 0.93 DRD1 (0.67) DRD1NPC1POLBXIAPTAS1R3
SCHEMBL17674691 0.92 DRD1 (0.53) DRD1NPC1POLBGAAKMT2A
SCHEMBL17674761 0.92 DRD1 (0.53) DRD1NPC1POLBGAAKMT2A
SCHEMBL20862347 0.88 DRD1 (0.50) DRD1POLBXIAPTAS1R3TAS1R1
SCHEMBL17670977 0.88 DRD1 (0.50) DRD1POLBXIAPTAS1R3TAS1R1
SCHEMBL17674644 0.83 DRD1 (0.61) DRD1NPC1POLBTAS1R3TAS1R1
SCHEMBL17674734 0.82 SMN1; SMN2 (0.61) DRD1NPC1POLBKMT2AMEN1
SCHEMBL20862352 0.81 DRD1 (0.57) DRD1POLBXIAPTAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170304292-A1 Tetrahydroisoquinoline Derivatives UCB BIOPHARMA SPRL (BE) 2017-10-26 — — US claimed
CN-107001278-B Tetrahydroisoquinoline derivatives UCB生物制药私人有限公司 2020-11-24 — — CN disclosed
EP-3204359-B1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2020-07-01 — — EP disclosed
US-10105359-B2 Tetrahydroisoquinoline derivatives UCB BIOPHARMA SPRL (BE) 2018-10-23 — — US disclosed
US-20170304292-A1 Tetrahydroisoquinoline Derivatives UCB BIOPHARMA SPRL (BE) 2017-10-26 — — US disclosed
EP-3204359-A1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB Biopharma SPRL (BE) 2017-08-16 — — EP disclosed
WO-2016055479-A1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2016-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304292-A1 Tetrahydroisoquinoline Derivatives OPRD1, ADRA1D, GPR52 DRD1 9/4885NPC1 1608/4885POLB 2513/4885
US-10105359-B2 Tetrahydroisoquinoline derivatives OPRD1, ADRA1D, GPR52 DRD1 9/4885NPC1 1608/4885POLB 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback